바이오스펙테이터

by Jongwon Jang

On the 18th, HLBKorea announced that they and their subsidiary LSKB have signed a memorandum of understanding (MOU) for a strategic partnership with Neopharm, a global pharmaceutical company in the United Arab Emirates (UAE).

HLBKorea plans to establish a sales network for Rivoceranib, a targeted anticancer drug, and actively pursues local pipeline clinical trials and exports of superior medicines in the Middle East area through this partnership.

Neo Pharma is a company run by Chairman of BR Shetty, the founder of NMC healthcare, the world's fourth-largest hospital chain. It is currently based in nine countries (US, UK, Japan, India, UAE, Russia, etc.), performing R&D, CRO, API manufacturing, and pharmaceutical sales.

Chang Jin Woo, a director of HLBKorea, said that "Despite Neo Pharma’s high interest in Rivoceranib, LSKB is in negotiations with co-marketing company for the European region. We are discussing building a sales network with Neo Pharma, which has the largest sales infrastructure in the Middle East and Middle East medicines markets such as Turkey, Iran, Egypt and Saudi Arabia, and is the best partner from the Middle East and India markets."

This strategic partnership will include a various range of co-works on pipeline of Neo Pharma and HLB Bio Group, including the sales and distributions of Rivoceranib, and details will soon be finalized through this agreement.

Meanwhile, LSKB will announce the direction of the third line drug for gastric cancer through the meeting with the FDA as soon as the data of Rivoceranib's global clinical trials are confirmed. The clinical results of Rivoceranib will be officially announced in the European Society of Medical Oncology (ESMO) at the end of September.